Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07140614
PHASE1

A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this study is to characterize the safety, tolerability, and pharmacokinetics of EDK060 as compared to placebo in adult patients with CMT1A.

Official title: A First-in-human, Multi-center, Randomized, Participant- and Investigator-blinded, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With Charcot-Marie Tooth Type 1A (CMT1A).

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

28

Start Date

2025-09-30

Completion Date

2028-02-26

Last Updated

2026-02-27

Healthy Volunteers

No

Interventions

DRUG

EDK060, dose A

EDK060, dose A, Single dose, IV infusion

DRUG

EDK060, dose B

EDK060, dose B, Single dose, IV infusion

DRUG

EDK060, dose C

EDK060, dose C, Single dose, IV infusion

DRUG

EDK060, dose D

EDK060, dose D, Single dose, IV infusion

OTHER

Placebo

Placebo

Locations (3)

Novartis Investigative Site

Ottawa, Ontario, Canada

Montreal Neurological Institute

Montreal, Quebec, Canada

CIUSS de l´Estrie-CHUS- Hôpital Fleurimont

Sherbrooke, Quebec, Canada